Safety and Efficacy of Adjuvant Therapy with Oxaliplatin, Leucovorin and 5-Fluorouracil After Mesorectal Excision with Lateral Pelvic Lymph Node Dissection for Stage III Lower Rectal Cancer.

Anticancer research

PubMedID: 25750348

Iwasa S, Souda H, Yamazaki K, Takahari D, Miyamoto Y, Takii Y, Ikeda S, Hamaguchi T, Kanemitsu Y, Shimada Y. Safety and Efficacy of Adjuvant Therapy with Oxaliplatin, Leucovorin and 5-Fluorouracil After Mesorectal Excision with Lateral Pelvic Lymph Node Dissection for Stage III Lower Rectal Cancer. Anticancer Res. 2015;35(3):1815-9.
BACKGROUND/AIM
Preoperative chemoradiotherapy followed by total mesorectal excision (TME) is the standard treatment for stage III lower rectal cancer worldwide. However, in Japan, the standard treatment is TME with lateral pelvic lymph node dissection (LPLD) followed by adjuvant chemotherapy. We examined the safety and efficacy of adjuvant therapy with oxaliplatin, leucovorin, and 5-fluorouracil (modified FOLFOX6) after TME with LPLD.

PATIENTS AND METHODS
This retrospective study included 33 patients who received modified FOLFOX6 after TME with LPLD for stage III lower rectal cancer.

RESULTS
The overall completion rate of 12 cycles of adjuvant modified FOLFOX6 was 76%. Grade 3 or 4 neutropenia was observed in eight patients (24%). Sensory neuropathy was observed in 32 patients (97%) with 4 (12%) having a grade 3 event. The disease-free survival (DFS) rate was 45% at 3 years.

CONCLUSION
Adjuvant modified FOLFOX6 was feasible in patients with stage III lower rectal cancer after TME with LPLD.